OMERS Administration Corp’s MoonLake Immunotherapeutics MLTX Stock Holding History

OMERS Administration Corp’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Buy	+19,500	New	+$353K	﹤0.01%	821
2022 Q2	–	Sell	-46,247	Closed	-$513K	–	459
2022 Q1	$513K	Buy	+46,247	New	+$460K	0.01%	135
2021 Q1	–	Sell	-10,000	Closed	-$108K	–	427
2020 Q4	$108K	Buy	+10,000	New	+$106K	﹤0.01%	239

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Weiss Asset Management Boston, Massachusetts $9.5B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

OMERS Administration Corp's MLTX Position: Q2 2026 in Review

OMERS Administration Corp opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 19,500 shares worth $380K. The stake represents ﹤0.01% of the portfolio and ranks #821 among its holdings. This is a return to the name: OMERS Administration Corp previously reported a position in MLTX as recently as Q1 2022.

OMERS Administration Corp first reported a position in MLTX in Q4 2020 and has held it in 3 quarters since. The position peaked at $513K in Q1 2022. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

OMERS Administration Corp held 19,500 shares of MoonLake Immunotherapeutics worth $380K as of Q2 2026.
MoonLake Immunotherapeutics was a new OMERS Administration Corp position in Q2 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q2 2026, its #821 holding.
OMERS Administration Corp first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 3 quarters since.
OMERS Administration Corp's MoonLake Immunotherapeutics position peaked at $513K in Q1 2022.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.